Revenue (Tables)

6 Months Ended

Jun. 30, 2024

Revenue from Contract with Customer [Abstract]

Schedule of disaggregation of revenue

	Three Months Ended June 30,				Six Months Ended June 30,
Revenue by product (in thousands)	2024		2023		2024		2023
MACI implants and kits
Implants based on contracted rate sold through a specialty pharmacy (a)	$	30,704	$	22,377	$	58,083	$	45,331
Implants subject to third party reimbursement sold through a specialty pharmacy (b)	3,332		4,015		6,529		8,004
Implants sold direct based on contracted rates (c)	8,099		7,252		14,501		14,222
Implants sold direct subject to third-party reimbursement (d)	965		1,045		2,150		1,538
Biopsy kits - direct bill	492		528		1,058		1,062
Change in estimates related to prior periods (e)	543		1,119		1,995		369
Total MACI implants and kits	44,135		36,336		84,316		70,526
Epicel
Direct bill (hospital)	7,758		9,586		18,422		16,413
NexoBrid (f)	769		—		1,205		—
Total revenue	$	52,662	$	45,922	$	103,943	$	86,939
(a) Represents implants sold through Orsini and AllCare whereby such specialty pharmacies have a direct contract with the underlying insurance provider. The amount of reimbursement is based on contracted rates at the time of sale supported by the pharmacy’s direct contracts.
(b) Represents implants sold through Orsini and AllCare whereby such specialty pharmacy does not have a direct contract with the underlying payer, and are subject to third-party reimbursement. The amount of reimbursement is established based on publicly available rates, fee schedules or past payer precedents.
(c) Represents implants sold directly from the Company to the facility based on a contract and known price agreed upon prior to the surgery date. Also represents direct sales under a contract to specialty distributor DMS.
(d) Represents implants sold directly from the Company to the facility based on a contract and known price agreed upon prior to the surgery date. The payment terms are subject to third-party reimbursement from an underlying insurance provider.
(e) Primarily represents changes in estimates related to implants sold through Orsini or AllCare and relate to changes to the initial expected reimbursement or collection expectations upon completion of the billing claims process. The change in estimates is a result of additional information, changes in collection expectations or actual cash collections received in the current period.
(f) Represents U.S. commercial revenue of NexoBrid.